In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those that don’t rely too heavily on international markets. When volatility hits, defensive sectors that are less affected by big-picture economic swings tend to come into focus.
One area drawing growing interest is large-cap biotech companies that operate primarily in the U.S. Investors see their domestic focus as a potential shield against the ripple effects of global trade disputes, offering a sense of security in an uncertain world.
